Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer
Purpose: Present a case of Mirvetuximab soravtansine (MIRV)-induced intraepithelial corneal deposits, review a proposed mechanism to explain the blurred vision our patient experienced, and explain clinical exams that may be used to support the diagnosis. Observations: A 63-year-old female with metas...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993625000246 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose: Present a case of Mirvetuximab soravtansine (MIRV)-induced intraepithelial corneal deposits, review a proposed mechanism to explain the blurred vision our patient experienced, and explain clinical exams that may be used to support the diagnosis. Observations: A 63-year-old female with metastatic ovarian cancer diagnosed with intraepithelial corneal deposits two weeks after her first MIRV infusion. Treatment with topical prednisolone acetate 1 % ophthalmic suspension and lubricating eye drops without interruption of her MIRV infusions resulted in complete resolution of blurry vision and corneal deposits. Conclusions and importance: The natural reversibility of MIRV-induced keratopathies underscores the need for prompt and regular ophthalmic assessments throughout drug administration. Understanding the mechanism behind these corneal changes, how to recognize them in a clinical setting, and expedite their reversal are essential to improve quality-of-life metrics in patients receiving MIRV transfusions. |
|---|---|
| ISSN: | 2451-9936 |